A Phase 2 interventional study of TS-172 10mg bid and TS-172 30mg bid in Hyperphosphatemia Patients on Hemodialysis, sponsored by Taisho Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Taisho Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Hyperphosphatemia with a site in Japan — 3 open to participants now, 4 under way, 4 of them phase 3. Hyperphosphatemia · Japan.
Among the 41 studies in Hyperphosphatemia with a site in Japan, this one is the 2nd largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2023, is one of 11 in phase 2, and was the 35th registered.
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
Browse Hyperphosphatemia studies →3 of the 41 studies in Hyperphosphatemia with a site in Japan are open now. Recruiting first, the newest first:
Taisho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Taisho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Taisho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 326 is above the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 117 across the 36 interventional studies, 762 across the 4 observational. Of the 36 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 41 have an industry lead sponsor. The 9 most frequent:
Taisho Pharmaceutical Co., Ltd. is the lead sponsor of 43 studies on the registry; 3 are open to participants now.
Taisho Pharmaceutical Co., Ltd. has 7 studies filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
4 of the studies in Hyperphosphatemia with a site in Japan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548840Phase 3Taisho Pharmaceutical Co., Ltd.A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | 2026-11-30 |
| NCT07285291Phase 3Taisho Pharmaceutical Co., Ltd.A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders | 2026-12-22 |
| NCT07548853Phase 3Taisho Pharmaceutical Co., Ltd.A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis | 2027-05-31 |
| NCT07285304Phase 3Taisho Pharmaceutical Co., Ltd.A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in Hyperphosphatemia with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive TS-172 10 mg bid.
Drug: TS-172 10mg bid
Patients receive TS-172 30 mg bid.
Drug: TS-172 30mg bid
Patients receive TS-172 60 mg bid.
Drug: TS-172 60mg bid
Patients receive TS-172 20 mg tid.
Drug: TS-172 20mg tid
Patients receive placebo.
Drug: Placebo
oral administration of TS-172 10 mg bid
oral administration of TS-172 30 mg bid
oral administration of TS-172 60 mg bid
oral administration of TS-172 20 mg tid
oral administration of placebo
Change from baseline in serum concentration of phosphorus
Time frame: Week 4
Achievement ratio of patients with the target serum concentration of phosphorus
Time frame: Up to Week 4
Concentration of corrected serum calcium
Time frame: Up to Week 4
Serum calcium times phosphorus product
Time frame: Up to Week 4
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Dec 2023, 10 months.
Of 13 phase 2 interventional studies under Hyperphosphatemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 10. This study's 10 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TS-172
Taisho Pharmaceutical Co., Ltd. →